Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
Status:
Completed
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess
the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular
Disease.
Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be
discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period
following the last dose of study treatment.
For the first approximately 20 participants effect of food will be evaluated on the
Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.